ARCHIVES

Single-Agent Phase III Trial Comparing Vectibix to Erbitux Meets Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 5 | May 31, 2013

Download PDF Visit The Full Archive

Related Articles

MD Anderson Expands Reach Into Florida, Ohio

September 26, 2014

FDA Staff Failed To Explain Approval Standards, Correct Misconceptions.

April 13, 2007

Benefits of Mammography Outweigh Harms In Women with Increased Risk, Starting at Age 40

April 27, 2012

Legislation Would Create Medicare Service For Comprehensive Cancer Care planning.

May 26, 2006

Judge Rules Privacy Act Not Applicable In Bernard Fisher’s Suit Against HHA

July 5, 1996

Targeting Men At High Risk Finds More Head & Neck Cancer

September 24, 2010